Department of Laboratory Medicine and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Methods Mol Biol. 2024;2797:13-22. doi: 10.1007/978-1-0716-3822-4_2.
Mutant forms of the RAS genes KRAS, NRAS, and HRAS are important and common drivers of cancer. Recently, two independent teams that integrated cancer genomics with cancer epidemiology estimated that approximately 15-20% of all human cancers harbor a mutation in one of these three RAS genes. These groups also estimate KRAS mutations occur in 11-14% of all human cancers. Although these estimates are lower than many commonly encountered values, these estimates continue to rank KRAS and the ensemble of RAS oncogenes among the most common genetic drivers of cancer across all forms of malignancy.
RAS 基因 KRAS、NRAS 和 HRAS 的突变形式是癌症的重要且常见驱动因素。最近，两个将癌症基因组学与癌症流行病学相结合的独立团队估计，大约 15-20%的所有人类癌症都携带有这三个 RAS 基因之一的突变。这两个团队还估计，KRAS 突变发生在 11-14%的所有人类癌症中。尽管这些估计值低于许多常见的数值，但这些估计值仍然将 KRAS 和 RAS 癌基因组合排在所有恶性肿瘤中最常见的癌症遗传驱动因素之列。
